ResearcherUniversitat Pompeu FabraActive in the last 2 years
Noemí Manero‐Rupérez
Matched on OpenAlex author ID A5011592922. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 19
2020: 1 paper · 2021: none · 2022: 2 papers · 2023: none · 2024: none · 2025: 1 paper · 2026: 1 paper
Papers 5
- PARP2 deficiency impairs pancreatic cancer progression by promoting genomic instability and antitumor immunity. First author DOI 10.1126/sciadv.adu8849↗
- Nuclear Galectin-1 promotes KRAS-dependent activation of pancreatic cancer stellate cells. Co-author DOI 10.1073/pnas.2424051122↗
- Soluble AXL is a novel blood marker for early detection of pancreatic ductal adenocarcinoma and differential diagnosis from chronic pancreatitis. Co-author DOI 10.1016/j.ebiom.2021.103797↗
- Sialyltransferase Inhibitor Ac53FaxNeu5Ac Reverts the Malignant Phenotype of Pancreatic Cancer Cells, and Reduces Tumor Volume and Favors T-Cell Infiltrates in… Co-author DOI 10.3390/cancers14246133↗
- The Galectin Family as Molecular Targets: Hopes for Defeating Pancreatic Cancer. Co-author DOI 10.3390/cells9030689↗
Closest collaborators
The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Neus Martínez‐Bosch · 5 shared papers, 2020–2026 · strength 0.86
- Paper PARP2 deficiency impairs pancreatic cancer progression by promoting genomic instability and antitumor immunity. DOI 10.1126/sciadv.adu8849↗
- Paper Nuclear Galectin-1 promotes KRAS-dependent activation of pancreatic cancer stellate cells. DOI 10.1073/pnas.2424051122↗
- Paper Sialyltransferase Inhibitor Ac53FaxNeu5Ac Reverts the Malignant Phenotype of Pancreatic Cancer Cells, and Reduces Tumor… DOI 10.3390/cancers14246133↗
- Pilar Navarro · 5 shared papers, 2020–2026 · strength 0.86
- Paper PARP2 deficiency impairs pancreatic cancer progression by promoting genomic instability and antitumor immunity. DOI 10.1126/sciadv.adu8849↗
- Paper Nuclear Galectin-1 promotes KRAS-dependent activation of pancreatic cancer stellate cells. DOI 10.1073/pnas.2424051122↗
- Paper Sialyltransferase Inhibitor Ac53FaxNeu5Ac Reverts the Malignant Phenotype of Pancreatic Cancer Cells, and Reduces Tumor… DOI 10.3390/cancers14246133↗
- Carmen E. Guerra · 2 shared papers, 2022–2026 · strength 0.36
- Paper PARP2 deficiency impairs pancreatic cancer progression by promoting genomic instability and antitumor immunity. DOI 10.1126/sciadv.adu8849↗
- Paper Soluble AXL is a novel blood marker for early detection of pancreatic ductal adenocarcinoma and differential diagnosis … DOI 10.1016/j.ebiom.2021.103797↗
- Laura Visa · 2 shared papers, 2020–2022 · strength 0.27
- Núria Vázquez-Bellón · 1 shared paper, 2026 · strength 0.23
- Renzo Emanuel Vera · 1 shared paper, 2025 · strength 0.20
- Judith Vinaixa · 1 shared paper, 2025 · strength 0.20
- Patricia Santofimia‐Castaño · 1 shared paper, 2025 · strength 0.20
- David R Pease · 1 shared paper, 2025 · strength 0.20
- Juan Iovanna · 1 shared paper, 2025 · strength 0.20
- Martín E. Fernández-Zapico · 1 shared paper, 2025 · strength 0.20
- Laura Miró · 1 shared paper, 2022 · strength 0.15
- Esther Llop · 1 shared paper, 2022 · strength 0.15
- Pedro Enrique Guerrero · 1 shared paper, 2022 · strength 0.15
- Rosa Peracaula · 1 shared paper, 2022 · strength 0.15
- Meritxell Gironella · 1 shared paper, 2022 · strength 0.13
- Alfredo Carrato · 1 shared paper, 2022 · strength 0.13
- Pablo Garcı́a de Frutos · 1 shared paper, 2022 · strength 0.13
- Julie Earl · 1 shared paper, 2022 · strength 0.13
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.